Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the discovery and development of novel oncology therapies targeting the tumor microenvironment. The company operates within the biopharmaceutical and oncology drug development industries, with an emphasis on biologics and small-molecule drugs designed to address solid tumors and metastatic cancers. Purple Biotech is publicly traded on the NASDAQ Capital Market under the ticker PPBT and is incorporated in Israel.
The company’s primary value drivers are its proprietary drug candidates, most notably CM24 (a monoclonal antibody targeting CEACAM1) and NT219 (a small-molecule inhibitor targeting cancer resistance mechanisms). Purple Biotech’s strategy centers on combination therapies intended to improve the efficacy of existing immuno-oncology treatments. Formerly known as Kitov Pharma Ltd, the company rebranded to Purple Biotech in 2020 to reflect its expanded oncology-focused pipeline and strategic repositioning.
Business Operations
Purple Biotech operates as a single-reportable segment focused on oncology drug research and development, generating no commercial revenue and relying primarily on equity financing, grants, and strategic collaborations to fund operations. Its activities include preclinical research, clinical trial execution, regulatory engagement, and intellectual property management. All product candidates remain in clinical or preclinical stages, and the company does not yet market approved therapies.
Operationally, research and development activities are conducted through Purple Biotech Israel Ltd, its principal operating subsidiary. The company collaborates with global pharmaceutical companies to evaluate its drug candidates in combination with approved immunotherapies, including checkpoint inhibitors. These collaborations are structured primarily as clinical and research agreements rather than revenue-generating commercial partnerships. Data inconclusive based on available public sources regarding long-term manufacturing or commercialization agreements.
Strategic Position & Investments
Purple Biotech’s strategy is centered on advancing differentiated oncology assets that can be combined with existing standard-of-care cancer treatments. CM24 is being evaluated in multiple clinical studies, including trials in colorectal and pancreatic cancers, while NT219 targets mechanisms of resistance to targeted therapies and immunotherapies. The company emphasizes biomarker-driven development and combination regimens as a means of improving clinical outcomes.
The company has not completed any transformative acquisitions in recent years and instead prioritizes internal pipeline development and selective collaborations. Purple Biotech has entered into clinical collaboration agreements with major pharmaceutical companies to study its candidates alongside approved oncology drugs; however, financial terms and long-term commercial rights vary by agreement. No material equity investments or diversified portfolio holdings outside its core oncology focus are disclosed in public filings.
Geographic Footprint
Purple Biotech is headquartered in Israel, with its principal executive offices and research management based in Rehovot, Israel. Clinical development activities are conducted internationally, including in the United States, Europe, and Israel, depending on trial design and regulatory requirements.
The company’s global footprint is primarily driven by multinational clinical trials rather than physical infrastructure. Regulatory interactions with the U.S. Food and Drug Administration (FDA) and other international health authorities play a central role in its operations, reflecting its focus on accessing major pharmaceutical markets despite a relatively lean geographic presence.
Leadership & Governance
Purple Biotech is led by an executive team with experience in biotechnology, pharmaceuticals, and clinical development. The leadership emphasizes capital discipline, strategic partnerships, and advancing a focused oncology pipeline through value-inflecting clinical milestones. Governance follows standards applicable to NASDAQ-listed life sciences companies, with oversight by an independent board of directors.
Key executives, as disclosed in recent public filings, include:
- Gil Efron – Chief Executive Officer
- Eyal Bar-Or – Chief Financial Officer
- Dr. Yifat Shapira – Chief Scientific Officer
- Ilana Shtarker – Chairperson of the Board
Data inconclusive based on available public sources regarding any recent changes to executive roles beyond those disclosed in the most recent filings.